Mumbai, 18 December 2019: CPhI & P-MEC India 2019 – organised by Informa Markets – recently closed its doors to over 45,000 visitors and 1,600+ exhibitors from 44 countries, making it the largest pharmaceutical trade show in South Asia. Mirroring the event’s success, India is set for rapid growth in 2020 according to the recent CPhI Annual Report Pharma Index.
Now in its 13th year, three days of CPhI & P-MEC India staged a breadth of informative content sessions, with pharma experts from across the entire supply chain sharing their knowledge. One key trend to emerge was the continued goal of aligning India to Western regulatory standards, which experts suggest will help the country sustain significant increases in exports if harmonization of regulations continues.
Innovation was another major talking point, with the widespread view that the current lack of innovation could potentially be one drag factor for India in the near future. Pharma experts discussed a number of proposed ideas for boosting innovation, including government investments in research initiatives and talent to form an ‘Innovation Hub’, as well as shifting manufacturing towards biologics development. In fact, raising regulatory standards and enhancing innovation are two crucial milestones the country must reach if the market is to achieve its ‘Vision 2030’ aspiration, which could result in a market valued at $130bn by the end of the next decade1.
There was huge interest in the latest machinery driven by the expanding production base in India. In response, P-MEC India was larger than any previous year, with cutting edge manufacturers displaying the newest commercial machinery and technologies on the market. Investing in the right technologies has become an integral part of industry efforts to prepare for the next wave of growth.
In its 4th consecutive year, India Pharma Week hosted a plethora of initiatives spanning over five days, giving executives the chance to engage in thought-provoking discussions about how to propel the country’s pharmaceutical market forward. Notably, the CEO roundtable saw pharma leaders explore the benefits of Indian companies tapping into the Chinese and Russian markets. For example, the Russian government provided a number of cost-saving incentives that Indian pharma could capitalise on.
The Pre-Connect Congress event brought together stakeholders from all aspects of the pharma supply chain to discuss the key drivers in Indian pharma for the upcoming year. On top of the aforementioned ‘improving regulatory compliance’ and ‘innovation’ topics, the implications of Pharma 4.0 and Artificial Intelligence were discussed, as well as the benefits of companies diversifying their generics portfolios.
CPhI & P-MEC India 2020 will take place at the India Expo Centre next November (25-27), with all market indicates pointing to an extremely prosperous few years ahead.
